November 13, 2008
BioReliance Corporation Announces That Sarah Sheridan, Ph.D. Will Deliver a Poster Presentation at the 16th Annual European Society of Gene and Cell Therapy Conference
BioReliance Corporation announced today that Dr. Sarah Sheridan, a Scientific Director in BioReliance's Glasgow, Scotland, facility, will deliver a poster presentation regarding her work in gene therapy biodistribution studies at the 16th Annual European Society of Gene and Cell Therapy conference to be held from November 13-16, 2008 in Bruges, Belgium.
BioReliance is a leading contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries worldwide.
Dr. Sheridan's presentation, entitled "Factors to Consider in Gene Therapy Biodistribution Studies," highlights the role that biodistribution studies play in the regulatory safety evaluation of genetic vaccines. Genetic vaccine technology has become an important strategy for the development of therapies for currently untreatable diseases. The biodistribution studies that will be described during Dr. Sheridan's presentation are designed to investigate integration or expression of the vaccine vector in the germ line, the persistence of the vector in the target tissue and the dissemination of the vector to non-target tissues.
Commenting on her upcoming presentation, Dr. Sheridan stated, "BioReliance is a world leader in developing the procedures for quantitative PCR assays in safety biodistribution studies. We use a combination of highly robust multi-well quantitative PCR technology and high-throughput nucleic acid extraction automated systems, which are the gold standard of biodistribution safety testing, to satisfy increasingly stringent regulatory guidelines in this important area of therapeutic innovation."
The European Society of Gene and Cell Therapy is one of the world's leading societies dedicated to the study of gene and cell transfer. Its annual conferences attract researchers from around the world who are advancing the use of gene transfer technologies in the treatment of a wide range of diseases, including currently incurable life-threatening disorders.
BioReliance is a leading specialist provider of cost-effective contract services to the pharmaceutical and biopharmaceutical industries, offering more than 1,000 tests or services related to biologics safety testing, in vitro and in vivo toxicology, viral manufacturing, GMP manufacturing, pre-clinical testing and lab animal health diagnostics. Founded in 1947 as Microbiological Associates, BioReliance is headquartered in Rockville, Maryland, and has primary facilities in Rockville, Glasgow, Scotland, and Stirling, Scotland, employing more than 700 people globally. For more information, visit www.bioreliance.com.